89bio: Pegozafermin Could Be A Game-Changer For Liver Disease – Strong Buy (NASDAQ:ETNB)

0

healthy liver highlighted blue - anatomy of healthy human

mi-viri

89bio, Inc. (NASDAQ:ETNB) is a clinical-stage biopharmaceutical company based in San Francisco, California. The company focuses on developing therapies for liver and cardiometabolic conditions with its drug candidate, pegozafermin. This medicine is a fibroblast growth factor 21 (FGF21) analog used to regulate metabolic

link

Leave a Reply

Your email address will not be published. Required fields are marked *